ZA202001834B - Dextromethorphan transdermal delivery device - Google Patents
Dextromethorphan transdermal delivery deviceInfo
- Publication number
- ZA202001834B ZA202001834B ZA2020/01834A ZA202001834A ZA202001834B ZA 202001834 B ZA202001834 B ZA 202001834B ZA 2020/01834 A ZA2020/01834 A ZA 2020/01834A ZA 202001834 A ZA202001834 A ZA 202001834A ZA 202001834 B ZA202001834 B ZA 202001834B
- Authority
- ZA
- South Africa
- Prior art keywords
- transdermal delivery
- delivery device
- dextromethorphan
- methods
- adhesive layer
- Prior art date
Links
- 230000037317 transdermal delivery Effects 0.000 title abstract 5
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 title abstract 4
- 229960001985 dextromethorphan Drugs 0.000 title abstract 4
- 239000012790 adhesive layer Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004907 flux Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000010410 layer Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568028P | 2017-10-04 | 2017-10-04 | |
| US201862680182P | 2018-06-04 | 2018-06-04 | |
| PCT/US2018/054178 WO2019070864A1 (en) | 2017-10-04 | 2018-10-03 | DEVICE FOR TRANSDERMAL DEXTROMETHORPHAN DELIVERY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202001834B true ZA202001834B (en) | 2024-10-30 |
Family
ID=65994772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/01834A ZA202001834B (en) | 2017-10-04 | 2020-03-23 | Dextromethorphan transdermal delivery device |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11382869B2 (enExample) |
| EP (1) | EP3691641A4 (enExample) |
| JP (2) | JP2020536953A (enExample) |
| KR (1) | KR20200062254A (enExample) |
| CN (1) | CN111343980B (enExample) |
| AU (1) | AU2018345723B2 (enExample) |
| BR (1) | BR112020006723A2 (enExample) |
| CA (1) | CA3078369A1 (enExample) |
| IL (1) | IL273735B2 (enExample) |
| MX (1) | MX2020003044A (enExample) |
| TW (1) | TWI795446B (enExample) |
| WO (1) | WO2019070864A1 (enExample) |
| ZA (1) | ZA202001834B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
| US20240216358A1 (en) * | 2020-03-30 | 2024-07-04 | Shinkei Therapeutics Llc | Transdermal delivery of dextromethorphan |
| CN117100750A (zh) * | 2020-07-20 | 2023-11-24 | 深圳信立泰药业股份有限公司 | 一种药物组合物及其应用 |
| JP2024503114A (ja) * | 2021-01-18 | 2024-01-24 | アンテシップ バイオベンチャーズ トゥー エルエルシー | 神経精神疾患に対する抗うつ剤とデキストロメトルファンとの組み合わせ |
| CN113720944B (zh) * | 2021-09-30 | 2023-04-28 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊含量的检测方法 |
| AU2023356341A1 (en) * | 2022-10-06 | 2025-05-15 | Shinkei Therapeutics, Inc. | Transdermal delivery of dextromethorphan |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3020630B2 (ja) * | 1991-03-27 | 2000-03-15 | 三井化学株式会社 | 薬物投与用粘着剤 |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| WO1995024172A1 (en) * | 1994-03-07 | 1995-09-14 | Theratech, Inc. | Drug-containing adhesive composite transdermal delivery device |
| SE9601528D0 (sv) * | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally administered dextromethorphan as antitissue agent |
| TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| WO2004017941A2 (en) * | 2002-08-20 | 2004-03-04 | Euro-Celtique, S.A. | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist |
| CA2548596A1 (en) * | 2003-12-10 | 2005-06-23 | Acrux Dds Pty Ltd. | Method of treatment for undesired effect following transdermal or topical drug delivery |
| US20060223786A1 (en) | 2005-04-01 | 2006-10-05 | Smith David J | Transdermal pain control method and device |
| BRPI0607017B8 (pt) * | 2005-04-06 | 2021-05-25 | Adamas Pharmaceuticals Inc | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc |
| KR20080097443A (ko) * | 2006-02-03 | 2008-11-05 | 아바니르 파마슈티컬스 | 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물 |
| US20070248657A1 (en) * | 2006-04-25 | 2007-10-25 | Smith David J | Multi-compartment transdermal pain control device |
| EA200970369A1 (ru) * | 2006-10-09 | 2009-08-28 | Смитклайн Бичам Корпорейшн | Композиции для снижения симптомов никотиновой абстиненции и/или отказа от употребления табака |
| WO2009021058A2 (en) * | 2007-08-06 | 2009-02-12 | Trinity Labortories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| WO2010062690A1 (en) * | 2008-10-30 | 2010-06-03 | Concert Pharmaceuticals Inc. | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
| JP5680061B2 (ja) * | 2009-04-24 | 2015-03-04 | ヘンケル・ユーエス・アイピー・リミテッド・ライアビリティ・カンパニーＨｅｎｋｅｌ ＵＳ ＩＰ ＬＬＣ | シリコーンアクリルハイブリッドポリマーを基剤とする接着剤 |
| US20140051718A1 (en) | 2012-04-16 | 2014-02-20 | Antecip Bioventures Ii Llc | Compositions and Methods Comprising Celecoxib or Related Compounds and Dextromethorphan |
| JP6605485B2 (ja) * | 2013-11-05 | 2019-11-13 | アンテシップ バイオベンチャーズ トゥー エルエルシー | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物 |
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
-
2018
- 2018-10-02 TW TW107134828A patent/TWI795446B/zh active
- 2018-10-03 CA CA3078369A patent/CA3078369A1/en active Pending
- 2018-10-03 WO PCT/US2018/054178 patent/WO2019070864A1/en not_active Ceased
- 2018-10-03 EP EP18864063.5A patent/EP3691641A4/en active Pending
- 2018-10-03 CN CN201880072989.3A patent/CN111343980B/zh active Active
- 2018-10-03 IL IL273735A patent/IL273735B2/en unknown
- 2018-10-03 KR KR1020207011696A patent/KR20200062254A/ko not_active Ceased
- 2018-10-03 US US16/753,471 patent/US11382869B2/en active Active
- 2018-10-03 AU AU2018345723A patent/AU2018345723B2/en active Active
- 2018-10-03 MX MX2020003044A patent/MX2020003044A/es unknown
- 2018-10-03 BR BR112020006723-7A patent/BR112020006723A2/pt unknown
- 2018-10-03 JP JP2020540680A patent/JP2020536953A/ja active Pending
-
2020
- 2020-03-23 ZA ZA2020/01834A patent/ZA202001834B/en unknown
-
2022
- 2022-07-06 US US17/858,471 patent/US20220331264A1/en not_active Abandoned
-
2023
- 2023-08-25 JP JP2023136898A patent/JP7609943B2/ja active Active
- 2023-10-19 US US18/381,849 patent/US20240189252A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL273735A (en) | 2020-05-31 |
| JP7609943B2 (ja) | 2025-01-07 |
| TW201922232A (zh) | 2019-06-16 |
| AU2018345723B2 (en) | 2024-09-19 |
| RU2020115169A3 (enExample) | 2022-02-16 |
| MX2020003044A (es) | 2020-08-13 |
| CN111343980A (zh) | 2020-06-26 |
| BR112020006723A2 (pt) | 2020-10-06 |
| CA3078369A1 (en) | 2019-04-11 |
| WO2019070864A1 (en) | 2019-04-11 |
| IL273735B2 (en) | 2024-08-01 |
| CN111343980B (zh) | 2024-02-27 |
| RU2020115169A (ru) | 2021-11-08 |
| US20220331264A1 (en) | 2022-10-20 |
| US11382869B2 (en) | 2022-07-12 |
| EP3691641A1 (en) | 2020-08-12 |
| IL273735B1 (en) | 2024-04-01 |
| KR20200062254A (ko) | 2020-06-03 |
| US20240189252A1 (en) | 2024-06-13 |
| AU2018345723A8 (en) | 2020-04-23 |
| JP2023159366A (ja) | 2023-10-31 |
| TWI795446B (zh) | 2023-03-11 |
| AU2018345723A1 (en) | 2020-04-16 |
| EP3691641A4 (en) | 2021-04-07 |
| JP2020536953A (ja) | 2020-12-17 |
| US20200323788A1 (en) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001834B (en) | Dextromethorphan transdermal delivery device | |
| PH12016500391A1 (en) | Site-specific antibody conjugation methods and compositions | |
| PH12018502738A1 (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| MX2017006653A (es) | Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión. | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX380273B (es) | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp. | |
| SG11201811697SA (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
| CL2018000222A1 (es) | Nueva combinación para el uso en el tratamiento del cáncer | |
| NZ725480A (en) | Anti-ptk7 antibody-drug conjugates | |
| MX2022008277A (es) | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. | |
| MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
| IN2014DN11099A (enExample) | ||
| AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
| NZ756730A (en) | Combination therapy with an anti-axl antibody-drug conjugate | |
| WO2015023649A3 (en) | Peptides for enhancing transdermal delivery | |
| GB2483505B (en) | Devices for transdermal drug delivery | |
| MX2020000651A (es) | Sistema de administracion transdermica con una membrana microporosa que tiene poros llenos de solvente. | |
| MX2017003638A (es) | Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos. | |
| MX366230B (es) | Composiciones multipolimericas para liberación transdermica de farmaco. | |
| CO2017009930A2 (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| MX375186B (es) | Composiciones de anfetamina transdérmica estable y métodos de fabricación. | |
| PH12017501930A1 (en) | Calicheamicin contructs and methods of use | |
| PH12018502139A1 (en) | Phosphaplatin liquid formulations | |
| MX2015010967A (es) | Formulaciones transdermicas de laquinimod. | |
| MX2014008693A (es) | Administracion transdermica de hormonas. |